Therapeutic targeting of Huntington's disease: Molecular and clinical approaches

Area of Science:

• Neuroscience
• Genetics
• Pharmacology

Background:

• Huntington's disease (HD) is an autosomal dominant, progressive neurodegenerative disorder.
• Pathology involves DNA, RNA, and protein abnormalities, classifying it as a protein-misfolding and expansion repeat disorder.
• Current treatments primarily manage symptoms; disease-modifying therapies are urgently needed.

Purpose of the Study:

• To review current disease-modifying therapies for HD in clinical development.
• To examine the pharmaceutical industry's approach to Huntington's disease drug development.
• To identify challenges hindering therapeutic success in HD.

Main Methods:

• Literature review of ongoing clinical trials for HD therapies.
• Analysis of pharmaceutical pipelines for Huntington's disease medications.
• Discussion of challenges in HD drug development and clinical trials.

Main Results:

• Several molecular therapies targeting HD's root cause are in clinical trials.
• A significant Phase III trial (tominersen) was discontinued due to risk-benefit concerns.
• Despite trial setbacks, optimism remains for gene-targeting approaches.

Conclusions:

• The landscape of Huntington's disease therapeutics is evolving, with a focus on molecular interventions.
• Challenges in clinical trials and pharmaceutical development persist but are being addressed.
• Continued research and development are crucial for finding effective disease-modifying treatments for HD.